BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

Myeloma

Genomic Testing

Conference

1rem

Conference Archive

Conferences

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies. 

Higher AFM24 Exposure Boosts Response in Advanced NSCLC: AACR Data

AACR Annual Meeting

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.  

Incorporating Genomics into Lymphoma Classification Can Improve Care

AMP Annual Meeting

A groundbreaking trial explores pembrolizumab's role in enhancing treatment outcomes for advanced head and neck cancer, promising significant advancements in patient care.

Advancing Head and Neck Cancer Treatment: Insights From KEYNOTE-689

ASCO Annual Meeting

Sara Char, MD, discusses how inflammatory diets impact colon cancer survival rates. 

Inflammatory Diet and Survival Outcomes in Colorectal Cancer

ASCO Annual Meeting: GI Spotlight

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases. 


Fakih Discusses Phase 2 Trial of Balstilimab Plus Botensilimab in MSS mCRC

ASCO Gastrointestinal Cancers Symposium

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.

Disparities in AML Highlight Need for Tailored Strategies for Elderly Patients 

ASH Annual Meeting

Ivosidenib (AG-120), an IDH1 inhibitor, demonstrated an objective response rate (ORR) of 41.6% in patients&nbsp;with relapsed/refractory&nbsp;<em>IDH1</em>-mutant acute myeloid leukemia (AML), according to findings from a single-arm phase I study.&nbsp;

Ivosidenib Demonstrates Responses in More Than 40% in Relapsed/Refractory IDH+ AML

ASH MPN Spotlight

BCMA/CD19 dual-targeting FasTCAR-T cells showed a high objective response rate in a study of patients with newly diagnosed high-risk multiple myeloma.

Novel CAR T-Cell Therapy Achieves 100% MRD Negativity in Patients With Newly-Diagnosed Myeloma 

ASH Multiple Myeloma Meeting Spotlight

Paul Richardson, MD, further discusses the data from the CC-92480-MM-002 trial, and future directions for research of mezigdomide combinations for patients with relapsed/refractory multiple myeloma.


Pharmacokinetic Results and Next Steps for Mezigdomide Combos in RRMM

ASH23 Spotlight: Mezigdomide in RRMM

An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.

Cabozantinib Continues to Improve PFS, Regardless of Duration of Previous Lenvatinib Therapy in RAI-Refractory DTC

ATA Annual Meeting

Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting. 

SunRISe-1 Highlights TAR-200 as Alternative to Surgery for High-Risk Bladder Cancer

AUA Annual Meeting

Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.

Ropeginterferon, Rusfertide Are Key to Reducing Thromboembolic Events in Polycythemia Vera

Annual International Congress on Hematologic Malignancies

Two oncologists explain how patients can better understand the NCCN Clinical Practice Guidelines.

How to Unpack the NCCN Guidelines for mTNBC

Annual School of Breast Oncology

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Chemotherapy Foundation Symposium

A study showed that a treatment regimen called BOVen was safe and effective in producing responses in older patients with mantle cell lymphoma.

New MCL Treatment Shows Promise for Older Patients: BOVen Regimen Well-Tolerated with High Response Rates 

EHA Congress

Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC. 

A Step Forward in c-Met-Targeted Therapy in NSCLC

ESMO Congress

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

What to Watch Out for at ASCO GI 2025: Key Abstracts for Community Oncologists

GI Cancers Symposium

Zev A. Wainberg, MD, discusses the impact of the COVID-19 on the colorectal cancer field specifically in terms of clinical trial research. 

The Importance of Maintaining CRC Clinical Trials Amidst the COVID-19 Pandemic

GI Symposium Colorectal Cancer Spotlight

Funda Meric-Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily pretreated locally advanced or metastatic urothelial cancer.

Updated Findings on Datopotamab Deruxtecan in Urothelial Cancer Treatment

Genitourinary Cancers Symposium

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer. 

In TROPION-Lung01, Dato-DXd Continues to Show Promise in NSCLC

IASLC World Conference on Lung Cancer

Pathologic complete responses were seen in 29% of patients with resectable hepatocellular carcinoma treated with a perioperative immunotherapy regimen in the first interim analysis of a phase II trial, reported Yehia I. Abugabal, MD, in his presentation at the 2019 ILCA Annual Conference.

Perioperative Nivolumab/Ipilimumab Combo Showing Early Promising Results in HCC

ILCA Annual Conference

Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.

Modern Approaches to Treating Neuroendocrine Tumors

ISGIO Annual Conference

In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development. 

Precision Oncology Inches into Head and Neck Cancer Paradigm

Inaugural Miami Cancer Institute Precision Oncology Symposium

Robert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment. 


Optimizing Prostate Cancer Care Moving Beyond PSA 

Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies

At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins. 

Case of Twins with Rare Stem Cell Disorder Wins Best Overall Abstract at Congress on MPNs

International Congress on MPN

Arnab Basu, MD, MPH, FACP, discusses molecular residual disease-guided adjuvant therapy in patients with renal cell carcinoma, highlighting the rationale and goals of the MRD gate RCC clinical trial.

Basu Provides an Overview of MRD GATE RCC

International Kidney Cancer Symposium

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.

Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma

International Myeloma Society Annual Meeting